Illexcor Therapeutics LLC
Altri Biotherapeutics is a preclinical-stage pharmaceutical company based in Richmond, VA, specializing in the development of therapeutic monoclonal antibodies (mAbs) targeting the insulin-like growth factor (IGF) signaling system for cancer treatment. With a focus on triple-negative breast cancer (TNBC) and plans to expand into other metastatic and invasive cancers, Altri has licensed patents from Virginia Commonwealth University to advance its innovative therapeutic approaches.
The company's lead candidate, ALT101, has demonstrated significant antitumor and antimetastatic activity in preclinical studies, particularly against TNBC, which disproportionately affects certain demographics and currently has limited treatment options. Altri aims to progress its therapeutic candidates toward IND filing and Phase III clinical trials, addressing critical unmet medical needs in cancer treatment.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.